Clinical manifestations, response to treatment, and clinical outcome for Weimaraners with hypertrophic osteodystrophy: 53 cases (2009-2011)

Noa Safra, Eric G Johnson, Lisa Lit, Oded Foreman, Zena T. Wolf, Miriam Aguilar, Nili Karmi, Carrie J Finno, Danika L Bannasch

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective-To evaluate clinical manifestations, response to treatment, and outcome for Weimaraners with hypertrophic osteodystrophy (HOD). Design-Retrospective case series. Animals-53 dogs. Procedures-Medical records were reviewed for signalment, vaccination history, clinical signs, laboratory test results, response to treatment, and relapses. Radiographs were reviewed. Results-Clinical signs included pyrexia, lethargy, and ostealgia; signs involving the gastrointestinal, ocular, or cutaneous systems were detected. Of the 53 dogs, 28 (52.8%) had HOD-affected littermates. Dogs with HOD-affected littermates were more likely to relapse, compared with the likelihood of relapse for dogs with no HOD-affected littermates. All 53 dogs had been vaccinated 1 to 30 days before HOD onset; no difference was found between the number of dogs with a history of vaccination with a recombinant vaccine (n = 21) versus a nonrecombinant vaccine (32). Fifty (94.3%) dogs had radiographic lesions compatible with HOD at disease onset, and the other 3 (5.7%) had HOD lesions 48 to 72 hours after the onset of clinical signs. Twelve of 22 (54.5%) dogs treated with NSAIDs did not achieve remission by 7 days after initiation of treatment. All dogs treated initially with corticosteroids achieved remission within 8 to 48 hours. Of the 33 dogs that reached adulthood, 28 (84.8%) were healthy and 5 (15.2%) had episodes of pyrexia and malaise. Conclusions and Clinical Relevance-Treatment with corticosteroids was superior to treatment with NSAIDs in Weimaraners with HOD. It may be necessary to evaluate repeated radiographs to establish a diagnosis of HOD. Most HOD-affected Weimaraners had resolution of the condition with physeal closure.

Original languageEnglish (US)
Pages (from-to)1260-1266
Number of pages7
JournalJournal of the American Veterinary Medical Association
Volume242
Issue number9
DOIs
StatePublished - May 1 2013

Fingerprint

Dogs
dogs
relapse
nonsteroidal anti-inflammatory agents
remission
Non-Steroidal Anti-Inflammatory Agents
adrenal cortex hormones
Recurrence
lesions (animal)
fever
Adrenal Cortex Hormones
Vaccination
Fever
vaccination
Lethargy
Synthetic Vaccines
recombinant vaccines
Therapeutics
adulthood
Medical Records

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Clinical manifestations, response to treatment, and clinical outcome for Weimaraners with hypertrophic osteodystrophy : 53 cases (2009-2011). / Safra, Noa; Johnson, Eric G; Lit, Lisa; Foreman, Oded; Wolf, Zena T.; Aguilar, Miriam; Karmi, Nili; Finno, Carrie J; Bannasch, Danika L.

In: Journal of the American Veterinary Medical Association, Vol. 242, No. 9, 01.05.2013, p. 1260-1266.

Research output: Contribution to journalArticle

@article{aaef9da63df34aa9861e209a7f628235,
title = "Clinical manifestations, response to treatment, and clinical outcome for Weimaraners with hypertrophic osteodystrophy: 53 cases (2009-2011)",
abstract = "Objective-To evaluate clinical manifestations, response to treatment, and outcome for Weimaraners with hypertrophic osteodystrophy (HOD). Design-Retrospective case series. Animals-53 dogs. Procedures-Medical records were reviewed for signalment, vaccination history, clinical signs, laboratory test results, response to treatment, and relapses. Radiographs were reviewed. Results-Clinical signs included pyrexia, lethargy, and ostealgia; signs involving the gastrointestinal, ocular, or cutaneous systems were detected. Of the 53 dogs, 28 (52.8{\%}) had HOD-affected littermates. Dogs with HOD-affected littermates were more likely to relapse, compared with the likelihood of relapse for dogs with no HOD-affected littermates. All 53 dogs had been vaccinated 1 to 30 days before HOD onset; no difference was found between the number of dogs with a history of vaccination with a recombinant vaccine (n = 21) versus a nonrecombinant vaccine (32). Fifty (94.3{\%}) dogs had radiographic lesions compatible with HOD at disease onset, and the other 3 (5.7{\%}) had HOD lesions 48 to 72 hours after the onset of clinical signs. Twelve of 22 (54.5{\%}) dogs treated with NSAIDs did not achieve remission by 7 days after initiation of treatment. All dogs treated initially with corticosteroids achieved remission within 8 to 48 hours. Of the 33 dogs that reached adulthood, 28 (84.8{\%}) were healthy and 5 (15.2{\%}) had episodes of pyrexia and malaise. Conclusions and Clinical Relevance-Treatment with corticosteroids was superior to treatment with NSAIDs in Weimaraners with HOD. It may be necessary to evaluate repeated radiographs to establish a diagnosis of HOD. Most HOD-affected Weimaraners had resolution of the condition with physeal closure.",
author = "Noa Safra and Johnson, {Eric G} and Lisa Lit and Oded Foreman and Wolf, {Zena T.} and Miriam Aguilar and Nili Karmi and Finno, {Carrie J} and Bannasch, {Danika L}",
year = "2013",
month = "5",
day = "1",
doi = "10.2460/javma.242.9.1260",
language = "English (US)",
volume = "242",
pages = "1260--1266",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "9",

}

TY - JOUR

T1 - Clinical manifestations, response to treatment, and clinical outcome for Weimaraners with hypertrophic osteodystrophy

T2 - 53 cases (2009-2011)

AU - Safra, Noa

AU - Johnson, Eric G

AU - Lit, Lisa

AU - Foreman, Oded

AU - Wolf, Zena T.

AU - Aguilar, Miriam

AU - Karmi, Nili

AU - Finno, Carrie J

AU - Bannasch, Danika L

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Objective-To evaluate clinical manifestations, response to treatment, and outcome for Weimaraners with hypertrophic osteodystrophy (HOD). Design-Retrospective case series. Animals-53 dogs. Procedures-Medical records were reviewed for signalment, vaccination history, clinical signs, laboratory test results, response to treatment, and relapses. Radiographs were reviewed. Results-Clinical signs included pyrexia, lethargy, and ostealgia; signs involving the gastrointestinal, ocular, or cutaneous systems were detected. Of the 53 dogs, 28 (52.8%) had HOD-affected littermates. Dogs with HOD-affected littermates were more likely to relapse, compared with the likelihood of relapse for dogs with no HOD-affected littermates. All 53 dogs had been vaccinated 1 to 30 days before HOD onset; no difference was found between the number of dogs with a history of vaccination with a recombinant vaccine (n = 21) versus a nonrecombinant vaccine (32). Fifty (94.3%) dogs had radiographic lesions compatible with HOD at disease onset, and the other 3 (5.7%) had HOD lesions 48 to 72 hours after the onset of clinical signs. Twelve of 22 (54.5%) dogs treated with NSAIDs did not achieve remission by 7 days after initiation of treatment. All dogs treated initially with corticosteroids achieved remission within 8 to 48 hours. Of the 33 dogs that reached adulthood, 28 (84.8%) were healthy and 5 (15.2%) had episodes of pyrexia and malaise. Conclusions and Clinical Relevance-Treatment with corticosteroids was superior to treatment with NSAIDs in Weimaraners with HOD. It may be necessary to evaluate repeated radiographs to establish a diagnosis of HOD. Most HOD-affected Weimaraners had resolution of the condition with physeal closure.

AB - Objective-To evaluate clinical manifestations, response to treatment, and outcome for Weimaraners with hypertrophic osteodystrophy (HOD). Design-Retrospective case series. Animals-53 dogs. Procedures-Medical records were reviewed for signalment, vaccination history, clinical signs, laboratory test results, response to treatment, and relapses. Radiographs were reviewed. Results-Clinical signs included pyrexia, lethargy, and ostealgia; signs involving the gastrointestinal, ocular, or cutaneous systems were detected. Of the 53 dogs, 28 (52.8%) had HOD-affected littermates. Dogs with HOD-affected littermates were more likely to relapse, compared with the likelihood of relapse for dogs with no HOD-affected littermates. All 53 dogs had been vaccinated 1 to 30 days before HOD onset; no difference was found between the number of dogs with a history of vaccination with a recombinant vaccine (n = 21) versus a nonrecombinant vaccine (32). Fifty (94.3%) dogs had radiographic lesions compatible with HOD at disease onset, and the other 3 (5.7%) had HOD lesions 48 to 72 hours after the onset of clinical signs. Twelve of 22 (54.5%) dogs treated with NSAIDs did not achieve remission by 7 days after initiation of treatment. All dogs treated initially with corticosteroids achieved remission within 8 to 48 hours. Of the 33 dogs that reached adulthood, 28 (84.8%) were healthy and 5 (15.2%) had episodes of pyrexia and malaise. Conclusions and Clinical Relevance-Treatment with corticosteroids was superior to treatment with NSAIDs in Weimaraners with HOD. It may be necessary to evaluate repeated radiographs to establish a diagnosis of HOD. Most HOD-affected Weimaraners had resolution of the condition with physeal closure.

UR - http://www.scopus.com/inward/record.url?scp=84876572915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876572915&partnerID=8YFLogxK

U2 - 10.2460/javma.242.9.1260

DO - 10.2460/javma.242.9.1260

M3 - Article

C2 - 23600784

AN - SCOPUS:84876572915

VL - 242

SP - 1260

EP - 1266

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 9

ER -